Prescribed for Sleep, Approved for Depression: Unpacking Trazodone's Off-Label Dominance and What the Evidence Actually Supports

There is a quiet contradiction embedded in nearly every trazodone prescription written in the United States. The drug's FDA approval, granted in 1981, covers major depressive disorder. Yet survey data and pharmacy claims consistently show that the majority of contemporary trazodone prescriptions are written not for depression, but for insomnia. A medication approved for one condition has become the go-to solution for another. Understanding how that happened—and whether the clinical evidence justifies it—matters for anyone who takes trazodone, prescribes it, or advises patients about it.

How Off-Label Prescribing Works in American Medicine

Off-label prescribing is neither illegal nor inherently problematic. Once the FDA approves a drug for any indication, licensed clinicians in the United States have broad legal authority to prescribe it for conditions beyond that approval. This flexibility exists because the clinical knowledge base often moves faster than the regulatory pipeline. Conducting a formal Phase III trial to earn a new indication is expensive and time-consuming, and pharmaceutical manufacturers have little financial incentive to pursue additional approvals for older, often generic drugs.

Trazodone fits that profile precisely. As a generic medication with no patent protection, no company stands to profit from funding the large-scale randomized controlled trials that would be required to secure an FDA sleep indication. The result is a regulatory gap: widespread clinical use without the formal evidentiary infrastructure that FDA approval typically demands.

This does not automatically mean the practice is wrong. What it does mean is that the burden of evaluating the evidence falls more squarely on clinicians and informed patients rather than on a regulatory body that has formally reviewed and endorsed a specific use.

What the Clinical Literature Actually Shows

The evidence supporting trazodone for insomnia is real but uneven. Several controlled studies—most of them relatively small and of short duration—demonstrate that trazodone at low doses (typically 25 mg to 100 mg) reduces sleep onset latency, decreases nighttime awakenings, and improves subjective sleep quality. These effects are largely attributed to the drug's potent antagonism of histamine H1 receptors and serotonin 5-HT2A receptors at low plasma concentrations, mechanisms that are pharmacologically distinct from its antidepressant action at higher doses.

However, the evidence base carries notable limitations. Most trials have followed patients for four to six weeks, leaving long-term efficacy and safety questions underexplored. Studies in primary insomnia populations—that is, patients without co-occurring depression or anxiety—are fewer than those conducted in mixed psychiatric cohorts. And the placebo-controlled data, while generally favorable for short-term outcomes, does not consistently demonstrate superiority over other pharmacological options across all sleep parameters.

The American Academy of Sleep Medicine's clinical practice guidelines reflect this complexity. While trazodone is widely used in clinical settings, it does not currently carry a strong recommendation from major sleep medicine bodies for primary chronic insomnia, partly because the evidence base does not yet meet the same threshold required of FDA-approved sleep agents such as doxepin, suvorexant, or lemborexant.

Why Prescribers Reach for Trazodone Anyway

Understanding the gap between guideline caution and real-world practice requires looking at the alternatives. Many FDA-approved sleep medications carry their own significant concerns. Benzodiazepines and Z-drugs such as zolpidem are associated with dependence, tolerance, cognitive impairment, and elevated fall risk, particularly in older adults. Newer orexin receptor antagonists are effective but considerably more expensive and less familiar to primary care physicians who write the bulk of sleep prescriptions.

Trazodone, by contrast, is inexpensive, widely available, non-scheduled under the Controlled Substances Act, and carries a relatively benign side effect profile at the low doses used for sleep. For clinicians managing patients with comorbid depression and insomnia—a combination that is extremely common—trazodone offers a single agent that may address both conditions simultaneously, which has obvious practical appeal.

The non-addictive classification is particularly significant in the current clinical environment. Amid ongoing concerns about prescription drug misuse, many clinicians are actively seeking sleep aids that do not carry a Schedule IV designation. Trazodone fills that role in a way that few alternatives do.

The Liability Question Providers Should Understand

Off-label prescribing does carry a distinct medico-legal dimension. When a physician prescribes a drug beyond its approved indication, the standard of care expectation shifts. Courts and licensing boards generally evaluate whether the prescriber had a rational scientific basis for the decision, documented the reasoning appropriately, and obtained adequate informed consent from the patient.

For trazodone and insomnia, the scientific basis is defensible. The pharmacological rationale is sound, and peer-reviewed literature supports the practice. However, documentation matters. Clinicians who prescribe trazodone for sleep without noting the off-label nature of that use—and without discussing it with the patient—may face greater professional exposure if an adverse event occurs. Patients, in turn, benefit from understanding that their prescription reflects a clinical judgment call rather than a formally approved indication, which affects how they should interpret efficacy expectations and weigh risk tolerance.

What Patients Should Ask Before Filling That Prescription

For patients who receive a trazodone prescription for sleep, several questions are worth raising with the prescribing clinician. First, is the insomnia primary or secondary? If sleep disruption is driven by underlying depression, anxiety, or pain, treating the root condition may be more appropriate than addressing the symptom alone. Second, have non-pharmacological options been adequately explored? Cognitive behavioral therapy for insomnia (CBT-I) is considered the first-line treatment for chronic insomnia by most clinical guidelines and has demonstrated superior long-term outcomes compared to pharmacotherapy.

Third, what is the intended duration of use? Trazodone's long-term sleep data is limited, and patients who begin taking it for situational insomnia may find themselves continuing indefinitely without a clear reassessment plan. Establishing a defined trial period and follow-up evaluation at the outset creates a more structured framework for decision-making.

The Broader Regulatory Conversation

Trazodone's off-label dominance also raises a systemic question about how the American pharmaceutical regulatory model handles older generic drugs. The FDA's approval process was not designed to retrospectively capture emerging evidence for drugs that have been in use for decades. No mechanism currently compels or incentivizes manufacturers to pursue new indications for off-patent compounds, even when substantial real-world use and clinical data exist.

Some clinicians and researchers have argued that a publicly funded pathway for evaluating generic drugs in new indications would serve patients better than the current system, which leaves significant prescribing decisions in a formal regulatory gray zone. Until such mechanisms exist, the trazodone-for-insomnia pattern will likely persist—driven by practical necessity, pharmacological logic, and the limits of what the market will fund.

A Measured Conclusion

Trazodone's off-label use for insomnia is neither reckless nor fully validated. It occupies an evidence-supported middle ground: backed by plausible mechanisms and a reasonable body of clinical data, but not yet evaluated at the scale that formal FDA approval demands. For patients and clinicians alike, the honest position is one of informed pragmatism—acknowledging what the evidence shows, understanding what it does not yet prove, and making decisions that reflect both the individual patient's circumstances and the current state of the science.